Additionally, it has been shown that BPC 157, even with a single administration, managed to control right heart failure, increased P wave amplitude, tachycardia, and ST elevation caused by acute thrombotic coronary occlusion in mice (6, 7, 8)
Looking forward, the horizon seems promising for GLP-1 agonists, with new formulations and combination therapies under investigation
Viking Therapeutics' VK-2735 - The New Kid On The Block Fresh off the press Viking reported statistically significant weight loss of 13% at 13-weeks, which didnt show signs of plateauing
Regular check-ins with your provider ensure your maintenance protocol continues to match your evolving health goals and any changes in your metabolic response
More human studies are needed